Publications
56
Citations
2,708
Est. group size
—
Recurring co-author estimate
Active years
15
Publishing since 2012
Kausik Umanath conducts clinical research in kidney medicine (nephrology), studying how chronic kidney disease, high blood pressure, and diabetes are connected and how they can be treated. Much of the work evaluates medications such as SGLT2 inhibitors and aldosterone synthase inhibitors, and explores biological markers of hard-to-control hypertension. The research also includes clinical trial analyses and case studies of kidney-related conditions.
Publication activity has been fairly steady over the past decade, averaging around two to three papers per year with some year-to-year variation.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~9 · 18% small-team papers (≤3 authors) · across 20 venues
- Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?
Current Hypertension Reports · 2026
- Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors
Frontiers in Cardiovascular Medicine · 2026
- S3698 CMV Colitis in Immunocompetent Host
The American Journal of Gastroenterology · 2024
- Abstract 71: Analysis of First Morning Urine Transcriptomes in Normotensive and Hypertensive Patients Identify Upregulated Inflammatory and Signaling Pathways Associated with Hypertension
Hypertension · 2024
- Abstract P331: Simple Instruction and Provision of Literature on Low Salt Diet Ineffective in Reducing Salt Intake in Patients with Hypertension
Hypertension · 2024
- A Unique Presentation of Lupus Podocytopathy with Collapsing FSGS Variant
Journal of the American Society of Nephrology · 2023
- Urine Cell Transcriptomes Implicate Specific Renal Inflammatory Pathways Associated With Difficult‐to‐Control Hypertension
Journal of the American Heart Association · 2023
- POS-255 EFFECT OF DAPAGLIFLOZIN ON BLOOD PRESSURE IN PATIENTS WITH CKD: A PRE-SPECIFIED ANALYSIS FROM DAPA-CKD
Kidney International Reports · 2022
- “Dip” in eGFR: Stay the Course With SGLT-2 Inhibition
Circulation · 2022
- Front Matter
Nephrology Self-Assessment Program · 2022
- A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
Kidney International · 2021
- High SARS-CoV-2 Viral Load in Urine Sediment Correlates with Acute Kidney Injury and Poor COVID-19 Outcome
Journal of the American Society of Nephrology · 2021
- Pharmacological Effects of Ex Vivo Mesenchymal Stem Cell Immunotherapy in Patients with Acute Kidney Injury and Underlying Systemic Inflammation
Stem Cells Translational Medicine · 2021
- Multinephron Segment Diuretic Therapy to Overcome Diuretic Resistance in Acute Heart Failure: A Single-Center Experience
Journal of Cardiac Failure · 2021
- Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
European Heart Journal · 2021
- American Journal of Kidney Diseases×4
- Hypertension×4
- Journal of the American Society of Nephrology×3
- Kidney International×2
- Journal of Behavioral Medicine×2
- Shunichi Fukuhara
Medicine · University of Michigan
- Mia Wang
Medicine · University of Michigan
- Ranjani N. Moorthi
Medicine · Indiana University
- Akram Al‐Makki
Medicine · Purdue University West Lafayette
- Bruce Robinson
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 27, 2026.
Claim or correct this profile